KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 107 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $78,030 | -97.3% | 58,231 | -96.3% | 0.00% | -100.0% |
Q2 2023 | $2,851,800 | -55.4% | 1,593,184 | -3.1% | 0.00% | -50.0% |
Q1 2023 | $6,398,793 | +216.7% | 1,644,934 | +176.8% | 0.00% | +300.0% |
Q4 2022 | $2,020,708 | -37.7% | 594,326 | +0.1% | 0.00% | -50.0% |
Q3 2022 | $3,242,000 | +20.9% | 593,817 | -0.1% | 0.00% | +100.0% |
Q2 2022 | $2,682,000 | -39.3% | 594,488 | -0.8% | 0.00% | -50.0% |
Q1 2022 | $4,418,000 | +1334.4% | 599,436 | +1149.7% | 0.00% | – |
Q4 2021 | $308,000 | -76.4% | 47,966 | -78.6% | 0.00% | -100.0% |
Q3 2021 | $1,307,000 | -44.1% | 224,636 | -0.9% | 0.00% | 0.0% |
Q2 2021 | $2,340,000 | -22.9% | 226,743 | -21.4% | 0.00% | -50.0% |
Q1 2021 | $3,035,000 | +15.4% | 288,553 | +69.8% | 0.00% | 0.0% |
Q4 2020 | $2,631,000 | +42.4% | 169,908 | +34.3% | 0.00% | +100.0% |
Q3 2020 | $1,848,000 | -57.8% | 126,552 | -45.2% | 0.00% | -66.7% |
Q2 2020 | $4,375,000 | +51.0% | 231,006 | +53.2% | 0.00% | 0.0% |
Q1 2020 | $2,897,000 | +48.0% | 150,825 | +47.5% | 0.00% | +200.0% |
Q4 2019 | $1,958,000 | +1116.1% | 102,230 | +509.4% | 0.00% | – |
Q3 2019 | $161,000 | -68.5% | 16,775 | -80.4% | 0.00% | – |
Q2 2019 | $511,000 | -90.4% | 85,632 | -90.6% | 0.00% | -100.0% |
Q1 2019 | $5,307,000 | +18.2% | 908,950 | +89.6% | 0.00% | 0.0% |
Q4 2018 | $4,489,000 | -57.1% | 479,323 | -22.0% | 0.00% | 0.0% |
Q3 2018 | $10,455,000 | -3.1% | 614,129 | -3.4% | 0.00% | 0.0% |
Q2 2018 | $10,795,000 | +324.8% | 635,421 | +235.3% | 0.00% | +200.0% |
Q1 2018 | $2,541,000 | +40.7% | 189,485 | +0.6% | 0.00% | 0.0% |
Q4 2017 | $1,806,000 | +1.5% | 188,373 | +16.1% | 0.00% | 0.0% |
Q3 2017 | $1,779,000 | +15.5% | 162,265 | -4.8% | 0.00% | 0.0% |
Q2 2017 | $1,540,000 | -10.3% | 170,468 | +27.4% | 0.00% | 0.0% |
Q1 2017 | $1,716,000 | +54.3% | 133,775 | +12.9% | 0.00% | 0.0% |
Q4 2016 | $1,112,000 | +16.9% | 118,466 | +21.0% | 0.00% | 0.0% |
Q3 2016 | $951,000 | +67.7% | 97,904 | +15.7% | 0.00% | – |
Q2 2016 | $567,000 | -37.9% | 84,598 | -17.4% | 0.00% | -100.0% |
Q1 2016 | $913,000 | -33.6% | 102,444 | -1.4% | 0.00% | 0.0% |
Q4 2015 | $1,375,000 | +50.4% | 103,950 | +19.7% | 0.00% | 0.0% |
Q3 2015 | $914,000 | -58.8% | 86,873 | +6.4% | 0.00% | 0.0% |
Q2 2015 | $2,220,000 | -33.2% | 81,639 | -24.8% | 0.00% | -50.0% |
Q1 2015 | $3,322,000 | -17.4% | 108,581 | +1.0% | 0.00% | 0.0% |
Q4 2014 | $4,023,000 | +43.9% | 107,540 | +34.3% | 0.00% | 0.0% |
Q3 2014 | $2,795,000 | +1355.7% | 80,047 | +1831.6% | 0.00% | – |
Q2 2014 | $192,000 | +163.0% | 4,144 | +73.2% | 0.00% | – |
Q1 2014 | $73,000 | -90.3% | 2,392 | -92.8% | 0.00% | -100.0% |
Q4 2013 | $756,000 | – | 33,030 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |